ARTLNasdaq

ARTELO BIOSCIENCES, INC.

Healthcare·Oncology·Phase 1·Solana Beach, CA, United States
OncologyNeurologyPainDermatologyPsychiatry

ARTELO BIOSCIENCES, INC. (ARTL): 3 pipeline candidates · ~26 mo cash runway. Updated within the last hour.

6.2/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway7.2

26.0 months

Financial Health7.7

D/E 0.88 · 10% dilution

Pipeline Maturity4.0

Lead: Phase 1

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for ARTELO BIOSCIENCES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$4.5M

Cash

$10.3M

Quarterly Burn

$1.2M

Runway

26.0 mo

Revenue

—

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Aug 2028
Today~29 mo out
Catalyst within runway

Pipeline (3 candidates)

DrugPhase
ART12.11Preclinical
ART26.12Phase 1
ART27.13Phase 1

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

8

Total value held

$400K

HolderSharesValue
vanguard capital management llc20,258$154K
kathmere capital management, llc13,250$100K
jane street group, llc13,079$99K
vanguard fiduciary trust co3,139$24K
citigroup inc3,076$23K
rothschild investment llc2$15
cwm, llc1$8
osaic holdings, inc.1$7
·CEO: Mr. Gregory D. Gorgas M.B.A.

Frequently asked questions

How many drug candidates are in ARTELO BIOSCIENCES, INC.'s pipeline?

ARTELO BIOSCIENCES, INC. (ARTL) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is ARTELO BIOSCIENCES, INC.'s lead drug candidate?

ARTELO BIOSCIENCES, INC.'s most advanced tracked candidate is ART12.11 (Preclinical) for Anxiety, depression, PTSD, and other potential indications (including epilepsy and insomnia).

What is ARTELO BIOSCIENCES, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, ARTELO BIOSCIENCES, INC. has approximately 26.0 months of cash runway.

What is ARTELO BIOSCIENCES, INC.'s market capitalization?

ARTELO BIOSCIENCES, INC.'s market capitalization is approximately $4.5M.

Who is the CEO of ARTELO BIOSCIENCES, INC.?

Mr. Gregory D. Gorgas M.B.A. is the chief executive officer of ARTELO BIOSCIENCES, INC. (ARTL).

Get the full picture on ARTELO BIOSCIENCES, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar